Table 1 Genetically engineered mouse models of PIK3CA mutations
From: PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data
Study | Mouse model | Transgenic versus knock-in | Inducible versus non-inducible | Penetrance | Tumor latency | Histology |
|---|---|---|---|---|---|---|
Tikoo et al. [48] | MMTV-Cre Pik3caH1047R | Site-specific | Non-inducible | 100% | Nulliparous mice: 484 days | Fibroadenoma (45%) |
Adenosquamous carcinoma (10%) | ||||||
Biparous mice: 393 days | Osteosarcoma (2.5%) | |||||
Yuan et al. [49] | MMTV-Cre Pik3caH1047R | Site-specific | Non-inducible | NR | Nulliparous mice: 492 days | Fibroadenoma (76.9%) |
Adenocarcinoma (15.4%) | ||||||
Multiparous mice: 465 days | Spindle cell neoplasia (7.7%) | |||||
Liu et al. [50] | MMTV-rtTA TetO-Pik3caH1047R | Transgenic | Inducible (doxycycline) | 95% | 7Â months | Solid (33%) |
Acinar (8%) | ||||||
Glandular (5%) | ||||||
Papillary (12%) | ||||||
Squamous metaplasia (15%) | ||||||
Mixed (28%) | ||||||
Adams et al. [47] | MMTV-CreNLST Pik3caH1047R | Transgenic | Non-inducible | NR | 5Â months | Adenosquamous carcinoma (51%) |
Adenomyoepithelioma (45%) | ||||||
Spindle cell neoplasia (1%) | ||||||
Poorly differentiated adenocarcinoma (3%) | ||||||
| Â | MMTV-CreNLST Pik3caH1047R; p53f/+ | Transgenic | Non-inducible | NR | <5Â months | Adenosquamous carcinoma (51%) |
Spindle cell/EMT tumor (33%) | ||||||
Radial scar lesion (10%) | ||||||
Poorly differentiated adenocarcinoma (5%) | ||||||
Meyer et al. [46] | WAPi-Cre Pik3caH1047R | Transgenic | Non-inducible | NR | Nulliparous mice: 219 days | Adenosquamous carcinoma (54.6%) |
Adenomyoepithelioma (22.7%) | ||||||
Parous mice: 140.3Â days | Adenocarcinoma with squamous metaplasia (13.6%) | |||||
Adenocarcinoma (9.1%) | ||||||
| Â | MMTV-Cre Pik3caH1047R | Transgenic | Non-inducible | 25% | Nulliparous mice: 214 days | Adenomyoepithelioma (100%) |